|
Indications And Usage Apraclonidine Ophthalmic Solution, Usp 0.5% As Base Is Indicated For Short-Term Adjunctive Therapy In Patients On Maximally Tolerated Medical Therapy Who Require Additional Iop Reduction. Patients On Maximally Tolerated Medical Therapy Who Are Treated With Apraclonidine Ophthalmic Solution, Usp 0.5% As Base To Delay Surgery Should Have Frequent Follow-Up Examinations And Treatment Should Be Discontinued If The Intraocular Pressure Rises Significantly. The Addition Of Apraclonidine Ophthalmic Solution, Usp 0.5% As Base To Patients Already Using Two Aqueous Suppressing Drugs (I.e., Beta-Blocker Plus Carbonic Anhydrase Inhibitor) As Part Of Their Maximally Tolerated Medical Therapy May Not Provide Additional Benefit. This Is Because Apraclonidine Ophthalmic Solution, Usp 0.5% As Base Is An Aqueous Suppressing Drug And The Addition Of A Third Aqueous Suppressant May Not Significantly Reduce Iop. The Iop Lowering Efficacy Of Apraclonidine Ophthalmic Solution, Usp 0.5% As Base Diminishes Over Time In Some Patients. This Loss Of Effect, Or Tachyphylaxis, Appears To Be An Individual Occurrence With A Variable Time Of Onset And Should Be Closely Monitored. The Benefit For Most Patients Is Less Than One Month.
|